Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines.

M. Lee, M. Draoui, F. Zia, A. Gazdar, H. Oie, G. Bepler, F. Bellot, C. Tarr, R. Kris, T. W. Moody

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The ability of monoclonal antibody (MAb 108), an immunoglobulin G (IgG)2a against the epidermal growth factor receptor (EGF-R), to interact with lung cancer cell lines was investigated. 125I-EGF bound with high affinity to non-small-cell lung cancer (NSCLC) cells, and MAb 108 inhibited specific binding of nine NSCLC cell lines in a dose-dependent manner (IC50 = 0.3-3 micrograms per ml). 125I-MAb 108 bound with high affinity (kd = 2 nM) to a single class of sites (Bmax = 70,000 per cell) using NSCLC neuroendocrine cell line NCI-H460. Specific 125I-MAb 108 binding was inhibited with high affinity by MAb 108 but not by a control antibody IgG using large-cell carcinoma cell line NCI-H1299. 125I-MAb 108 binding was not internalized at 37 degrees C using NSCLC neuroendocrine cell line NCI-H460 and adenocarcinoma cell line NCI-H23. Also, 1 microgram per ml of MAb 108 but not of a control IgG inhibited the clonal growth of NCI-H23 and squamous cell carcinoma cell line NCI-H157 in vitro. Also, MAb 108 inhibited xenograft formation of cell lines NCI-H460, NCI-H157, and NCI-H727 in nude mice in vivo. After a palpable tumor had formed using NCI-H460 cells, injection of 100 micrograms of MAb 108 (intraperitoneally three times weekly) inhibited xenograft volume in nude mice by approximately 50%. These data suggest that MAb 108 may interact with EGF receptors on lung cancer cell lines and inhibit NSCLC proliferation.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalJournal of the National Cancer Institute. Monographs
Issue number13
StatePublished - 1992

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Monoclonal Antibodies
Cell Line
Non-Small Cell Lung Carcinoma
Growth
Neuroendocrine Cells
Immunoglobulin G
Heterografts
Nude Mice
Large Cell Carcinoma
Epidermal Growth Factor
Inhibitory Concentration 50
Squamous Cell Carcinoma
Adenocarcinoma
Injections
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lee, M., Draoui, M., Zia, F., Gazdar, A., Oie, H., Bepler, G., ... Moody, T. W. (1992). Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. Journal of the National Cancer Institute. Monographs, (13), 117-123.

Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. / Lee, M.; Draoui, M.; Zia, F.; Gazdar, A.; Oie, H.; Bepler, G.; Bellot, F.; Tarr, C.; Kris, R.; Moody, T. W.

In: Journal of the National Cancer Institute. Monographs, No. 13, 1992, p. 117-123.

Research output: Contribution to journalArticle

Lee, M, Draoui, M, Zia, F, Gazdar, A, Oie, H, Bepler, G, Bellot, F, Tarr, C, Kris, R & Moody, TW 1992, 'Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines.', Journal of the National Cancer Institute. Monographs, no. 13, pp. 117-123.
Lee, M. ; Draoui, M. ; Zia, F. ; Gazdar, A. ; Oie, H. ; Bepler, G. ; Bellot, F. ; Tarr, C. ; Kris, R. ; Moody, T. W. / Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. In: Journal of the National Cancer Institute. Monographs. 1992 ; No. 13. pp. 117-123.
@article{1e738c9a988b4de1b2393d2735c95a64,
title = "Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines.",
abstract = "The ability of monoclonal antibody (MAb 108), an immunoglobulin G (IgG)2a against the epidermal growth factor receptor (EGF-R), to interact with lung cancer cell lines was investigated. 125I-EGF bound with high affinity to non-small-cell lung cancer (NSCLC) cells, and MAb 108 inhibited specific binding of nine NSCLC cell lines in a dose-dependent manner (IC50 = 0.3-3 micrograms per ml). 125I-MAb 108 bound with high affinity (kd = 2 nM) to a single class of sites (Bmax = 70,000 per cell) using NSCLC neuroendocrine cell line NCI-H460. Specific 125I-MAb 108 binding was inhibited with high affinity by MAb 108 but not by a control antibody IgG using large-cell carcinoma cell line NCI-H1299. 125I-MAb 108 binding was not internalized at 37 degrees C using NSCLC neuroendocrine cell line NCI-H460 and adenocarcinoma cell line NCI-H23. Also, 1 microgram per ml of MAb 108 but not of a control IgG inhibited the clonal growth of NCI-H23 and squamous cell carcinoma cell line NCI-H157 in vitro. Also, MAb 108 inhibited xenograft formation of cell lines NCI-H460, NCI-H157, and NCI-H727 in nude mice in vivo. After a palpable tumor had formed using NCI-H460 cells, injection of 100 micrograms of MAb 108 (intraperitoneally three times weekly) inhibited xenograft volume in nude mice by approximately 50{\%}. These data suggest that MAb 108 may interact with EGF receptors on lung cancer cell lines and inhibit NSCLC proliferation.",
author = "M. Lee and M. Draoui and F. Zia and A. Gazdar and H. Oie and G. Bepler and F. Bellot and C. Tarr and R. Kris and Moody, {T. W.}",
year = "1992",
language = "English (US)",
pages = "117--123",
journal = "NCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "13",

}

TY - JOUR

T1 - Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines.

AU - Lee, M.

AU - Draoui, M.

AU - Zia, F.

AU - Gazdar, A.

AU - Oie, H.

AU - Bepler, G.

AU - Bellot, F.

AU - Tarr, C.

AU - Kris, R.

AU - Moody, T. W.

PY - 1992

Y1 - 1992

N2 - The ability of monoclonal antibody (MAb 108), an immunoglobulin G (IgG)2a against the epidermal growth factor receptor (EGF-R), to interact with lung cancer cell lines was investigated. 125I-EGF bound with high affinity to non-small-cell lung cancer (NSCLC) cells, and MAb 108 inhibited specific binding of nine NSCLC cell lines in a dose-dependent manner (IC50 = 0.3-3 micrograms per ml). 125I-MAb 108 bound with high affinity (kd = 2 nM) to a single class of sites (Bmax = 70,000 per cell) using NSCLC neuroendocrine cell line NCI-H460. Specific 125I-MAb 108 binding was inhibited with high affinity by MAb 108 but not by a control antibody IgG using large-cell carcinoma cell line NCI-H1299. 125I-MAb 108 binding was not internalized at 37 degrees C using NSCLC neuroendocrine cell line NCI-H460 and adenocarcinoma cell line NCI-H23. Also, 1 microgram per ml of MAb 108 but not of a control IgG inhibited the clonal growth of NCI-H23 and squamous cell carcinoma cell line NCI-H157 in vitro. Also, MAb 108 inhibited xenograft formation of cell lines NCI-H460, NCI-H157, and NCI-H727 in nude mice in vivo. After a palpable tumor had formed using NCI-H460 cells, injection of 100 micrograms of MAb 108 (intraperitoneally three times weekly) inhibited xenograft volume in nude mice by approximately 50%. These data suggest that MAb 108 may interact with EGF receptors on lung cancer cell lines and inhibit NSCLC proliferation.

AB - The ability of monoclonal antibody (MAb 108), an immunoglobulin G (IgG)2a against the epidermal growth factor receptor (EGF-R), to interact with lung cancer cell lines was investigated. 125I-EGF bound with high affinity to non-small-cell lung cancer (NSCLC) cells, and MAb 108 inhibited specific binding of nine NSCLC cell lines in a dose-dependent manner (IC50 = 0.3-3 micrograms per ml). 125I-MAb 108 bound with high affinity (kd = 2 nM) to a single class of sites (Bmax = 70,000 per cell) using NSCLC neuroendocrine cell line NCI-H460. Specific 125I-MAb 108 binding was inhibited with high affinity by MAb 108 but not by a control antibody IgG using large-cell carcinoma cell line NCI-H1299. 125I-MAb 108 binding was not internalized at 37 degrees C using NSCLC neuroendocrine cell line NCI-H460 and adenocarcinoma cell line NCI-H23. Also, 1 microgram per ml of MAb 108 but not of a control IgG inhibited the clonal growth of NCI-H23 and squamous cell carcinoma cell line NCI-H157 in vitro. Also, MAb 108 inhibited xenograft formation of cell lines NCI-H460, NCI-H157, and NCI-H727 in nude mice in vivo. After a palpable tumor had formed using NCI-H460 cells, injection of 100 micrograms of MAb 108 (intraperitoneally three times weekly) inhibited xenograft volume in nude mice by approximately 50%. These data suggest that MAb 108 may interact with EGF receptors on lung cancer cell lines and inhibit NSCLC proliferation.

UR - http://www.scopus.com/inward/record.url?scp=0026493493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026493493&partnerID=8YFLogxK

M3 - Article

C2 - 1327029

AN - SCOPUS:0026493493

SP - 117

EP - 123

JO - NCI Monographs

JF - NCI Monographs

SN - 1052-6773

IS - 13

ER -